Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer.

Mirlekar B, Michaud D, Searcy R, Greene K, Pylayeva-Gupta Y.

Cancer Immunol Res. 2018 Sep;6(9):1014-1024. doi: 10.1158/2326-6066.CIR-17-0710. Epub 2018 Jul 6.

PMID:
29980536
2.

Chromatin Remodeling Protein SMAR1 Is a Critical Regulator of T Helper Cell Differentiation and Inflammatory Diseases.

Mirlekar B, Gautam D, Chattopadhyay S.

Front Immunol. 2017 Feb 9;8:72. doi: 10.3389/fimmu.2017.00072. eCollection 2017. Review.

3.

Carbon nanospheres mediated delivery of nuclear matrix protein SMAR1 to direct experimental autoimmune encephalomyelitis in mice.

Chemmannur SV, Bhagat P, Mirlekar B, Paknikar KM, Chattopadhyay S.

Int J Nanomedicine. 2016 May 12;11:2039-51. doi: 10.2147/IJN.S93571. eCollection 2016.

4.

Regulation of T cell lineage commitment by SMAR1 during inflammatory & autoimmune diseases.

Mirlekar B, Majumdar S, Khetmalas M, Chattopadhyay S.

Indian J Med Res. 2015 Oct;142(4):405-13. doi: 10.4103/0971-5916.169198.

5.

MAR binding protein SMAR1 favors IL-10 mediated regulatory T cell function in acute colitis.

Mirlekar B, Patil S, Bopanna R, Chattopadhyay S.

Biochem Biophys Res Commun. 2015 Aug 21;464(2):647-53. doi: 10.1016/j.bbrc.2015.07.028. Epub 2015 Jul 10.

PMID:
26168735
6.

Nuclear matrix protein SMAR1 control regulatory T-cell fate during inflammatory bowel disease (IBD).

Mirlekar B, Ghorai S, Khetmalas M, Bopanna R, Chattopadhyay S.

Mucosal Immunol. 2015 Nov;8(6):1184-200.

7.

Nuclear matrix binding protein SMAR1 regulates T-cell differentiation and allergic airway disease.

Chemmannur SV, Badhwar AJ, Mirlekar B, Malonia SK, Gupta M, Wadhwa N, Bopanna R, Mabalirajan U, Majumdar S, Ghosh B, Chattopadhyay S.

Mucosal Immunol. 2015 Nov;8(6):1201-11. doi: 10.1038/mi.2015.11. Epub 2015 Mar 4.

8.

Supplemental Content

Loading ...
Support Center